JP2019510052A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019510052A5 JP2019510052A5 JP2018551147A JP2018551147A JP2019510052A5 JP 2019510052 A5 JP2019510052 A5 JP 2019510052A5 JP 2018551147 A JP2018551147 A JP 2018551147A JP 2018551147 A JP2018551147 A JP 2018551147A JP 2019510052 A5 JP2019510052 A5 JP 2019510052A5
- Authority
- JP
- Japan
- Prior art keywords
- strain
- composition
- vibrio
- icp
- strains
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 57
- 241001515965 unidentified phage Species 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 37
- 208000015181 infectious disease Diseases 0.000 claims description 30
- 230000002101 lytic effect Effects 0.000 claims description 29
- 241000607598 Vibrio Species 0.000 claims description 26
- 101001044255 Entamoeba histolytica Amoebiasin-2 Proteins 0.000 claims description 20
- 206010008631 Cholera Diseases 0.000 claims description 18
- 230000001580 bacterial effect Effects 0.000 claims description 15
- 231100000331 toxic Toxicity 0.000 claims description 13
- 230000002588 toxic effect Effects 0.000 claims description 13
- 101001042083 Entamoeba histolytica Amoebiasin-1 Proteins 0.000 claims description 12
- 241000607626 Vibrio cholerae Species 0.000 claims description 9
- 241000894007 species Species 0.000 claims description 9
- 210000002845 virion Anatomy 0.000 claims description 9
- 239000002158 endotoxin Substances 0.000 claims description 8
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 8
- 239000003242 anti bacterial agent Substances 0.000 claims description 7
- 231100000252 nontoxic Toxicity 0.000 claims description 7
- 230000003000 nontoxic effect Effects 0.000 claims description 7
- 208000035143 Bacterial infection Diseases 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 6
- 229940088710 antibiotic agent Drugs 0.000 claims description 5
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 5
- 241000282412 Homo Species 0.000 claims description 4
- 238000010171 animal model Methods 0.000 claims description 4
- 229940118696 vibrio cholerae Drugs 0.000 claims description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 230000002458 infectious effect Effects 0.000 claims description 3
- 230000002934 lysing effect Effects 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 230000000069 prophylactic effect Effects 0.000 claims description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 230000007613 environmental effect Effects 0.000 claims description 2
- 230000003449 preventive effect Effects 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 241000607337 Aliivibrio logei Species 0.000 claims 2
- 241000122170 Aliivibrio salmonicida Species 0.000 claims 2
- 241001600138 Aliivibrio wodanis Species 0.000 claims 2
- 241001453243 Campylobacter sputorum subsp. bubulus Species 0.000 claims 2
- 241000305093 Enterovibrio calviensis Species 0.000 claims 2
- 241000303324 Glaciibacter superstes Species 0.000 claims 2
- 241000466024 Isotomurus gallicus Species 0.000 claims 2
- 241000736255 Istiompax indica Species 0.000 claims 2
- 241000279652 Ixora casei Species 0.000 claims 2
- 241000287530 Psittaciformes Species 0.000 claims 2
- 241000332146 Vibrio aerogenes Species 0.000 claims 2
- 241001135143 Vibrio aestuarianus Species 0.000 claims 2
- 241001656470 Vibrio agarivorans Species 0.000 claims 2
- 241001231453 Vibrio albensis Species 0.000 claims 2
- 241001500064 Vibrio areninigrae Species 0.000 claims 2
- 241000452627 Vibrio artabrorum Species 0.000 claims 2
- 241001672646 Vibrio atlanticus Species 0.000 claims 2
- 241000549284 Vibrio atypicus Species 0.000 claims 2
- 241000674191 Vibrio azureus Species 0.000 claims 2
- 241000681719 Vibrio brasiliensis Species 0.000 claims 2
- 241000607323 Vibrio campbellii Species 0.000 claims 2
- 241000690888 Vibrio chagasii Species 0.000 claims 2
- 241000607296 Vibrio cincinnatiensis Species 0.000 claims 2
- 241001407018 Vibrio coralliilyticus Species 0.000 claims 2
- 241001025870 Vibrio crassostreae Species 0.000 claims 2
- 241000219284 Vibrio cyclitrophicus Species 0.000 claims 2
- 241000607306 Vibrio diazotrophicus Species 0.000 claims 2
- 241001349548 Vibrio ezurae Species 0.000 claims 2
- 241000607291 Vibrio fluvialis Species 0.000 claims 2
- 241001552433 Vibrio fortis Species 0.000 claims 2
- 241001148070 Vibrio furnissii Species 0.000 claims 2
- 241000607339 Vibrio gazogenes Species 0.000 claims 2
- 241001180047 Vibrio gigantis Species 0.000 claims 2
- 241000607618 Vibrio harveyi Species 0.000 claims 2
- 241000694781 Vibrio hepatarius Species 0.000 claims 2
- 241000210080 Vibrio hippocampi Species 0.000 claims 2
- 241000276415 Vibrio hispanicus Species 0.000 claims 2
- 241001268204 Vibrio ichthyoenteri Species 0.000 claims 2
- 241000690894 Vibrio kanaloae Species 0.000 claims 2
- 241000965623 Vibrio lentus Species 0.000 claims 2
- 241000369309 Vibrio litoralis Species 0.000 claims 2
- 241000607334 Vibrio mediterranei Species 0.000 claims 2
- 241001135144 Vibrio metschnikovii Species 0.000 claims 2
- 241000501793 Vibrio mytili Species 0.000 claims 2
- 241000607365 Vibrio natriegens Species 0.000 claims 2
- 241001148073 Vibrio navarrensis Species 0.000 claims 2
- 241000681718 Vibrio neptunius Species 0.000 claims 2
- 241000607359 Vibrio nereis Species 0.000 claims 2
- 241001135145 Vibrio nigripulchritudo Species 0.000 claims 2
- 241001135140 Vibrio orientalis Species 0.000 claims 2
- 241000690895 Vibrio pacinii Species 0.000 claims 2
- 241000607272 Vibrio parahaemolyticus Species 0.000 claims 2
- 241000896074 Vibrio pectenicida Species 0.000 claims 2
- 241001490532 Vibrio penaeicida Species 0.000 claims 2
- 241000092104 Vibrio ponticus Species 0.000 claims 2
- 241000607269 Vibrio proteolyticus Species 0.000 claims 2
- 241001407024 Vibrio rotiferianus Species 0.000 claims 2
- 241001086881 Vibrio ruber Species 0.000 claims 2
- 241000193098 Vibrio scophthalmi Species 0.000 claims 2
- 241001148079 Vibrio splendidus Species 0.000 claims 2
- 241000510690 Vibrio tapetis Species 0.000 claims 2
- 241001148039 Vibrio tubiashii Species 0.000 claims 2
- 241000607265 Vibrio vulnificus Species 0.000 claims 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- 241000251468 Actinopterygii Species 0.000 claims 1
- 241000271566 Aves Species 0.000 claims 1
- 241000282472 Canis lupus familiaris Species 0.000 claims 1
- 241000283086 Equidae Species 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 101710116435 Outer membrane protein Proteins 0.000 claims 1
- 241001520316 Phascolarctidae Species 0.000 claims 1
- 241000283984 Rodentia Species 0.000 claims 1
- 241000607284 Vibrio sp. Species 0.000 claims 1
- 230000001857 anti-mycotic effect Effects 0.000 claims 1
- 230000000842 anti-protozoal effect Effects 0.000 claims 1
- 239000002543 antimycotic Substances 0.000 claims 1
- -1 antiprotozoals Substances 0.000 claims 1
- 229940036589 antiprotozoals Drugs 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000002778 food additive Substances 0.000 claims 1
- 235000013373 food additive Nutrition 0.000 claims 1
- 230000036571 hydration Effects 0.000 claims 1
- 238000006703 hydration reaction Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 244000144972 livestock Species 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 238000009155 rehydration therapy Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 13
- 230000035772 mutation Effects 0.000 description 13
- 241000894006 Bacteria Species 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000000427 antigen Substances 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 206010012735 Diarrhoea Diseases 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000012010 growth Effects 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 230000001320 lysogenic effect Effects 0.000 description 4
- 230000001018 virulence Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- 230000005757 colony formation Effects 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000000366 juvenile effect Effects 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 101150055431 ompU gene Proteins 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108700023313 Bacteriophage Receptors Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 2
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 206010022678 Intestinal infections Diseases 0.000 description 2
- 102400000058 Neuregulin-1 Human genes 0.000 description 2
- 108090000556 Neuregulin-1 Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 201000009881 secretory diarrhea Diseases 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 101150021331 toxR gene Proteins 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 239000000304 virulence factor Substances 0.000 description 2
- 230000007923 virulence factor Effects 0.000 description 2
- NGZXDRGWBULKFA-NSOVKSMOSA-N (+)-Bebeerine Chemical compound C([C@@H]1N(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CCN3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 NGZXDRGWBULKFA-NSOVKSMOSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 101100284517 Aneurinibacillus thermoaerophilus hddC gene Proteins 0.000 description 1
- QMMRCKSBBNJCMR-KMZPNFOHSA-N Angiotensin III Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCN=C(N)N)C(C)C)C1=CC=C(O)C=C1 QMMRCKSBBNJCMR-KMZPNFOHSA-N 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 102400000348 Angiotensin-3 Human genes 0.000 description 1
- 101800000738 Angiotensin-3 Proteins 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 101000645291 Bos taurus Metalloproteinase inhibitor 2 Proteins 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229940122097 Collagenase inhibitor Drugs 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- 101710105759 Major outer membrane porin Proteins 0.000 description 1
- 101710164702 Major outer membrane protein Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
- 101000773513 Methanopyrus kandleri (strain AV19 / DSM 6324 / JCM 9639 / NBRC 100938) Uncharacterized protein MK0525 Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010039438 Salmonella Infections Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102000002938 Thrombospondin Human genes 0.000 description 1
- 108060008245 Thrombospondin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 244000268342 Viscaria vulgaris Species 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940124572 antihypotensive agent Drugs 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 210000003578 bacterial chromosome Anatomy 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 230000001420 bacteriolytic effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000002442 collagenase inhibitor Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 101150039741 hldD gene Proteins 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000002743 insertional mutagenesis Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 206010039447 salmonellosis Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662316704P | 2016-04-01 | 2016-04-01 | |
| US62/316,704 | 2016-04-01 | ||
| PCT/US2017/025305 WO2017173229A1 (en) | 2016-04-01 | 2017-03-31 | Methods and compositions for preventing infection by a vibrio species |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019510052A JP2019510052A (ja) | 2019-04-11 |
| JP2019510052A5 true JP2019510052A5 (cg-RX-API-DMAC7.html) | 2019-05-30 |
Family
ID=59966476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018551147A Pending JP2019510052A (ja) | 2016-04-01 | 2017-03-31 | Ｖｉｂｒｉｏ種による感染を防止するための方法および組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10953053B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3436611A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2019510052A (cg-RX-API-DMAC7.html) |
| KR (4) | KR102755264B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN109310722A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3026327A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017173229A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0811530B1 (pt) | 2007-05-14 | 2019-01-02 | Research Foundation Of State Univ Of New York | composição compreendendo indutor(es) de resposta fisiológica à dispersão ácido decanóico, superfície, solução, método ex vivo de tratamento ou inibição da formação de um biofilme sobre uma superfície |
| CN107904214A (zh) * | 2017-10-13 | 2018-04-13 | 深圳先进技术研究院 | 溶藻弧菌噬菌体及包含该噬菌体的杀菌组合物 |
| CN107904211B (zh) * | 2017-10-13 | 2024-03-19 | 深圳先进技术研究院 | 副溶血弧菌噬菌体及包含该噬菌体的杀菌组合物 |
| CN107904213A (zh) * | 2017-10-13 | 2018-04-13 | 深圳先进技术研究院 | 溶藻弧菌噬菌体及包含该噬菌体的杀菌组合物 |
| CN107904212A (zh) * | 2017-10-13 | 2018-04-13 | 深圳先进技术研究院 | 溶藻弧菌噬菌体及包含该噬菌体的杀菌组合物 |
| CN107805630B (zh) * | 2017-10-13 | 2024-03-19 | 深圳先进技术研究院 | 副溶血弧菌噬菌体及包含该噬菌体的杀菌组合物 |
| CN107805629B (zh) * | 2017-10-13 | 2023-03-21 | 深圳先进技术研究院 | 溶藻弧菌噬菌体及包含该噬菌体的杀菌组合物 |
| CN108048409A (zh) * | 2017-11-20 | 2018-05-18 | 深圳先进技术研究院 | 裂性弧菌噬菌体ValLY-3及包含该噬菌体的杀菌组合物及其应用 |
| CN108048412A (zh) * | 2017-11-20 | 2018-05-18 | 深圳先进技术研究院 | 裂性弧菌噬菌体ValLY-4及包含该噬菌体的杀菌组合物及其应用 |
| CN107988171A (zh) * | 2017-11-20 | 2018-05-04 | 深圳先进技术研究院 | 裂性弧菌噬菌体ValSw4-1及包含该噬菌体的杀菌组合物及其应用 |
| CN108070570A (zh) * | 2017-11-20 | 2018-05-25 | 深圳先进技术研究院 | 裂性弧菌噬菌体ValDsh-1及包含该噬菌体的杀菌组合物及其应用 |
| CN108048411A (zh) * | 2017-11-20 | 2018-05-18 | 深圳先进技术研究院 | 裂性弧菌噬菌体ValLY-2及包含该噬菌体的杀菌组合物及其应用 |
| CN108048410B (zh) * | 2017-11-20 | 2023-06-27 | 深圳先进技术研究院 | 裂性弧菌噬菌体VspSw-1及包含该噬菌体的杀菌组合物及其应用 |
| CN107988172A (zh) * | 2017-11-20 | 2018-05-04 | 深圳先进技术研究院 | 裂性弧菌噬菌体VpaJT-1及包含该噬菌体的杀菌组合物及其应用 |
| EP3798304B1 (en) * | 2018-05-22 | 2024-12-11 | Jichi Medical University | Antibacterial phage, treatment composition, disinfectant, food, kit for identifying bacteria, method for producing treatment composition, method for eliminating bacteria, method for identifying bacteria, and method for treating animals |
| CN109517804B (zh) * | 2018-11-19 | 2022-06-14 | 扬州大学 | 一种具有跨种裂解特性的拟态弧菌噬菌体oy-1、制备方法及其应用 |
| CN110352880B (zh) * | 2019-08-13 | 2021-04-20 | 宁波大学 | 一种紫菜黄斑病的治疗方法 |
| CN112391358B (zh) * | 2019-08-14 | 2023-12-01 | 宁波大学 | 地中海弧菌烈性噬菌体vB_VmeM-Yong及其应用 |
| CN111826309A (zh) * | 2020-06-30 | 2020-10-27 | 武汉合缘绿色生物股份有限公司 | 一种液体生物营养菌剂及其制备方法 |
| CN112029733B (zh) * | 2020-09-24 | 2021-11-26 | 瑞科盟(青岛)生物工程有限公司 | 一株高裂解性溶藻弧菌噬菌体rdp-vp-19001及其应用 |
| CN112011520B (zh) * | 2020-10-30 | 2021-01-19 | 中国科学院南海海洋研究所 | 一种调控珊瑚菌群的温和噬菌体VneM1及其应用 |
| CN112553171B (zh) * | 2020-12-27 | 2022-06-21 | 威海长青海洋科技股份有限公司 | 一种弧菌噬菌体制剂及其应用 |
| CN112646786A (zh) * | 2021-01-21 | 2021-04-13 | 海南海壹水产种苗有限公司 | 一株坎式弧菌噬菌体快速初步分离方法 |
| CN113201505B (zh) * | 2021-04-02 | 2023-12-29 | 青岛诺安百特生物技术有限公司 | 一株具备跨种裂解能力的溶藻弧菌噬菌体、其噬菌体组合物及其应用 |
| KR102774411B1 (ko) * | 2021-10-27 | 2025-02-27 | 전북대학교산학협력단 | 재증식 풀 컬쳐 기반 박테리오파지 스크리닝 방법 |
| CN116103183A (zh) * | 2022-03-30 | 2023-05-12 | 山东科技大学 | 一株脱除高盐硬水中钙离子的巨大弧菌及其应用 |
| CN114774371B (zh) * | 2022-06-21 | 2022-09-13 | 中国海洋大学 | 一种弧菌噬菌体及其应用 |
| CN115820569B (zh) * | 2022-08-09 | 2025-01-14 | 青岛诺安百特生物技术有限公司 | 一株奥氏弧菌噬菌体、其噬菌体组合物及其应用 |
| KR20240058217A (ko) | 2022-10-25 | 2024-05-03 | 주식회사 엘지에너지솔루션 | 고분자 고체 전해질 및 이의 제조방법 |
| CN120058874B (zh) * | 2025-04-29 | 2025-09-09 | 中国疾病预防控制中心传染病预防控制所 | 噬菌体蛋白Gp37及其在制备抑制霍乱弧菌定植和毒素分泌的制剂中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU699322B2 (en) | 1994-04-05 | 1998-12-03 | Exponential Biotherapies, Inc. | Antibacterial therapy with genotypically modified bacteriophage |
| JP2003519650A (ja) | 2000-01-11 | 2003-06-24 | イントラリティックス，インコーポレーテッド | 生体複合材料を製造するための生分解性マトリックスとしてのポリマーブレンド |
| US8956628B2 (en) * | 2007-12-13 | 2015-02-17 | Zoetis Products Llc | Bacteriophage preparations and method of use thereof |
| CL2012002902A1 (es) * | 2012-10-17 | 2013-05-03 | Univ Chile | Cepas de bacteriofagos especifica contra bacterias pertenecientes al genero vibrio para la profilaxis y terapia de vibrio anguillarum; y composicion antibacteriana que comprende dicha cepas. |
| WO2014070225A1 (en) * | 2012-10-30 | 2014-05-08 | Deerland Enzymes, Inc. | Prebiotic compositions comprising one or more types of bacteriophage |
| EP3041498B1 (en) * | 2013-09-05 | 2022-02-16 | Massachusetts Institute of Technology | Tuning microbial populations with programmable nucleases |
-
2017
- 2017-03-31 KR KR1020237030274A patent/KR102755264B1/ko active Active
- 2017-03-31 KR KR1020237043358A patent/KR20240005101A/ko not_active Ceased
- 2017-03-31 EP EP17776749.8A patent/EP3436611A4/en not_active Withdrawn
- 2017-03-31 WO PCT/US2017/025305 patent/WO2017173229A1/en not_active Ceased
- 2017-03-31 CA CA3026327A patent/CA3026327A1/en not_active Abandoned
- 2017-03-31 CN CN201780033655.0A patent/CN109310722A/zh active Pending
- 2017-03-31 JP JP2018551147A patent/JP2019510052A/ja active Pending
- 2017-03-31 KR KR1020187031275A patent/KR20190005846A/ko not_active Ceased
- 2017-03-31 KR KR1020227033895A patent/KR20220138015A/ko not_active Ceased
-
2018
- 2018-09-28 US US16/145,836 patent/US10953053B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019510052A5 (cg-RX-API-DMAC7.html) | ||
| US10953053B2 (en) | Methods and compositions for preventing infection by a Vibrio species | |
| CN101861387B (zh) | 新型噬菌体和包含所述噬菌体的抗菌组合物 | |
| CN101970644B (zh) | 新型噬菌体和包含所述噬菌体的抗菌组合物 | |
| CN102596219B (zh) | 噬菌体和包含所述噬菌体的抗菌组合物 | |
| JP2011514802A (ja) | 新規バクテリオファージおよびこれを含む抗菌組成物 | |
| AU2016209252B2 (en) | Novel Shigella bacteriophages and uses thereof | |
| JP5872700B2 (ja) | 新規バクテリオファージ及びそれを含む抗菌組成物 | |
| US20160076004A1 (en) | Novel bacteriophage and antibacterial composition comprising the same | |
| CA2541941C (en) | Anti-bacterial phage tail compositions and uses thereof | |
| US8846368B2 (en) | Bacteriophage and antibacterial composition comprising the same | |
| Nicolas et al. | In ovo administration of a phage cocktail partially prevents colibacillosis in chicks | |
| Pyzik et al. | Experimental Phage Therapies in Companion Animals with A Historical Review | |
| EP4111865B1 (en) | Antibacterial formulation of a mixture of bacteriophages for use in preventing or treating diseases caused by salmonella spp. | |
| US8771936B2 (en) | Bacteriophage and antibacterial composition comprising the same | |
| RU2717451C1 (ru) | Штамм бактериофага Pseudomonas aeruginosa N 323 (500317), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов | |
| US20250041367A1 (en) | Bacteriophages and use thereof for the treatment or prevention of infection caused by e. coli | |
| BR112022006931B1 (pt) | Formulação antibacteriana compreendendo uma mistura de bacteriófagos; uso e método de prevenção ou tratamento de doenças causadas por salmonella spp. em animais de fazenda por administração oral da formulação | |
| Carrias | Evaluation of biological agents for controlling enteric septicemia of catfish | |
| Lopes | Combined Inativation of Escherichia Coli by Phages and Antibiotics | |
| Jamalludeen | Phages against porcine post-weaning diarrhea due to O149 Escherichia coli |